HPRA CERTIFIED

HPRA
An tÚdarás Rialála Táirgí Sláinte
Health Products Regulatory Authority

Health Products Regulatory Authority

CERTIFICATE NUMBER: *19617/ASR12228/00001*

CERTIFICATE OF GMP COMPLIANCE OF A MANUFACTURER [1, 2]

Part 1

Issued following an inspection in accordance with :
Art. 111(5) of Directive 2001/83/EC as amended

The competent authority of Ireland confirms the following:
The manufacturer: ***SK Biotek Ireland Limited***
Site address: ***Watery Lane, Swords, Co. Dublin, K67 AY91, Ireland***

Is an active substance manufacturer that has been inspected in accordance with Art. 111(1) of Directive 2001/83/EC transposed in the following national legislation:
Medicinal Products (Control of Manufacture) Regulations 2007 to 2013.

From the knowledge gained during inspection of this manufacturer, the latest of which was conducted on ***2017-01-13*** , it is considered that it complies with :

- The principles of GMP for active substances [3] referred to in Article 47 of Directive 2001/83/EC .

This certificate reflects the status of the manufacturing site at the time of the inspection noted above and should not be relied upon to reflect the compliance status if more than three years have elapsed since the date of that inspection. However, this period of validity may be reduced or extended using regulatory risk management principles by an entry in the Restrictions or Clarifying remarks field. This certificate is valid only when presented with all pages and both Parts 1 and 2. The authenticity of this certificate may be verified in EudraGMDP. If it does not appear, please contact the issuing authority.

---

[1] *The certificate referred to in paragraph 111(5) of Directive 2001/83/EC and 80(5) of Directive 2001/82/EC, shall also be required for imports coming from third countries into a Member State.*

[2] *Guidance on the interpretation of this template can be found in the Help menu of EudraGMDP database.*

[3] *These requirements fulfil the GMP recommendations of WHO.*

I certify this is an original document.

Vincent Shannon

VINCENT SHANNON
NOTARY PUBLIC
29 Main Street, Swords
County Dublin, Ireland

Health Products Regulatory Authority
Document Reviewed by:
HPRA Reference: CI/0245 Comp-1
Date: 23rd January 2018

An tÚdarás Rialála Táirgí Sláinte, Teach Kevin O'Malley, Ionad Phort an Iarla, Ardán Phort an Iarla, Baile Átha Cliath 2, Éire
Health Products Regulatory Authority, Kevin O'Malley House, Earlsfort Centre, Earlsfort Terrace, Dublin 2, Ireland
T: +353 1 676 4971 • F: +353 1 676 7836 • info@hpra.ie • www.hpra.ie

APOSTILLE
(Convention de La Haye du 5 octobre 1961)

1. Country: Pays/País:	**IRELAND**
This public document Le présent acte public / El presente documento público	
2. has been signed by a été signé par ha sido firmado por	Vincent Shannon
3. acting in the capacity of agissant en qualité de quien actúa en calidad de	Notary Public
4. bears the seal / stamp of est revêtu du sceau / timbre de y está revestido del sello / timbre de	--------

Certified
Attesté / Certificado

5. at à / en	Dublin	**6. the** le / el día	22/03/2018
7. by par / por	Department of Foreign Affairs and Trade		
8. No sous no bajo el número	4232422018		
9. Seal / stamp: Sceau / timbre: Sello / timbre:	**10. Signature:** Signature: Firma: K Sexton		

This Apostille only certifies the authenticity of the signature and the capacity of the person who has signed the public document and, where appropriate, the identity of the seal or stamp which the public document bears. This Apostille does not certify the content of the document for which it was issued. To verify the issuance of this Apostille, see www.authentications.dfat.ie

AN ROINN GNÓTHAÍ EACHTRACHA AGUS TRÁDÁLA
DEPARTMENT OF FOREIGN AFFAIRS AND TRADE

Part 2

Manufacture of active substance. Names of substances subject to inspection :
APIXABAN(en)
ATAZANAVIR SULPHATE(en)
DACLATASVIR DIHYDROCHLORIDE(en)
DAPAGLIFLOZIN PROPANEDIOL(en)
DASATINIB(en)
ENTECAVIR(en)
IXABEPILONE(en)
SAXAGLIPTIN(en)
BECLABUVIR HYDROCHLORIDE (en)

3. MANUFACTURING OPERATIONS - ACTIVE SUBSTANCES

Active Substance : APIXABAN

3.1	**Manufacture of Active Substance by Chemical Synthesis**
	3.1.1 Manufacture of active substance intermediates 3.1.2 Manufacture of crude active substance 3.1.3 Salt formation / Purification steps : Crystallisation (Purification Step Only)
3.5	**General Finishing Steps**
	3.5.1 Physical processing steps : Drying 3.5.2 Primary Packaging (enclosing / sealing the active substance within a packaging material which is in direct contact with the substance) 3.5.3 Secondary Packaging (placing the sealed primary package within an outer packaging material or container. This also includes any labelling of the material which could be used for identification or traceability (lot numbering) of the active substance)
3.6	**Quality Control Testing**
	3.6.1 Physical / Chemical testing

Active Substance : ATAZANAVIR SULPHATE

3.1	**Manufacture of Active Substance by Chemical Synthesis**
	3.1.1 Manufacture of active substance intermediates 3.1.2 Manufacture of crude active substance 3.1.3 Salt formation / Purification steps : Crystallisation
3.5	**General Finishing Steps**
	3.5.1 Physical processing steps : Drying, Delumping 3.5.2 Primary Packaging (enclosing / sealing the active substance within a packaging material which is in direct contact with the substance) 3.5.3 Secondary Packaging (placing the sealed primary package within an outer packaging material or container. This also includes any labelling of the material which could be used for

	identification or traceability (lot numbering) of the active substance)
3.6	**Quality Control Testing**
	3.6.1 Physical / Chemical testing

Active Substance : DACLATASVIR DIHYDROCHLORIDE

3.1	**Manufacture of Active Substance by Chemical Synthesis**
	3.1.1 Manufacture of active substance intermediates 3.1.2 Manufacture of crude active substance 3.1.3 Salt formation / Purification steps : Crystallisation
3.5	**General Finishing Steps**
	3.5.1 Physical processing steps : Drying, Delumping 3.5.2 Primary Packaging (enclosing / sealing the active substance within a packaging material which is in direct contact with the substance) 3.5.3 Secondary Packaging (placing the sealed primary package within an outer packaging material or container. This also includes any labelling of the material which could be used for identification or traceability (lot numbering) of the active substance)
3.6	**Quality Control Testing**
	3.6.1 Physical / Chemical testing

Active Substance : DAPAGLIFLOZIN PROPANEDIOL

3.1	**Manufacture of Active Substance by Chemical Synthesis**
	3.1.1 Manufacture of active substance intermediates 3.1.2 Manufacture of crude active substance 3.1.3 Salt formation / Purification steps : Crystallisation (purification step only)
3.5	**General Finishing Steps**
	3.5.1 Physical processing steps : Drying 3.5.2 Primary Packaging (enclosing / sealing the active substance within a packaging material which is in direct contact with the substance) 3.5.3 Secondary Packaging (placing the sealed primary package within an outer packaging material or container. This also includes any labelling of the material which could be used for identification or traceability (lot numbering) of the active substance)
3.6	**Quality Control Testing**
	3.6.1 Physical / Chemical testing

Active Substance : DASATINIB

3.1	**Manufacture of Active Substance by Chemical Synthesis**
	3.1.1 Manufacture of active substance intermediates 3.1.2 Manufacture of crude active substance 3.1.3 Salt formation / Purification steps :

	Crystallisation (Purification Step Only)
3.5	**General Finishing Steps**
	3.5.1 Physical processing steps : Drying , Delumping 3.5.2 Primary Packaging (enclosing / sealing the active substance within a packaging material which is in direct contact with the substance) 3.5.3 Secondary Packaging (placing the sealed primary package within an outer packaging material or container. This also includes any labelling of the material which could be used for identification or traceability (lot numbering) of the active substance)
3.6	**Quality Control Testing**
	3.6.1 Physical / Chemical testing

Active Substance : ENTECAVIR

3.1	**Manufacture of Active Substance by Chemical Synthesis**
	3.1.1 Manufacture of active substance intermediates 3.1.2 Manufacture of crude active substance 3.1.3 Salt formation / Purification steps : Crystallisation (Purification step Only)
3.5	**General Finishing Steps**
	3.5.1 Physical processing steps : Drying, Wet Milling 3.5.2 Primary Packaging (enclosing / sealing the active substance within a packaging material which is in direct contact with the substance) 3.5.3 Secondary Packaging (placing the sealed primary package within an outer packaging material or container. This also includes any labelling of the material which could be used for identification or traceability (lot numbering) of the active substance)
3.6	**Quality Control Testing**
	3.6.1 Physical / Chemical testing

Active Substance : IXABEPILONE

3.1	**Manufacture of Active Substance by Chemical Synthesis**
	3.1.2 Manufacture of crude active substance 3.1.3 Salt formation / Purification steps : Crystallisation (Purification Steps Only)
3.5	**General Finishing Steps**
	3.5.1 Physical processing steps : Drying 3.5.2 Primary Packaging (enclosing / sealing the active substance within a packaging material which is in direct contact with the substance) 3.5.3 Secondary Packaging (placing the sealed primary package within an outer packaging material or container. This also includes any labelling of the material which could be used for identification or traceability (lot numbering) of the active substance)
3.6	**Quality Control Testing**
	3.6.1 Physical / Chemical testing

	3.6.2 Microbiological testing excluding sterility testing

Active Substance : SAXAGLIPTIN	
3.1	**Manufacture of Active Substance by Chemical Synthesis**
	3.1.1 Manufacture of active substance intermediates 3.1.2 Manufacture of crude active substance 3.1.3 Salt formation / Purification steps : Crystallisation (Purification Step Only)
3.5	**General Finishing Steps**
	3.5.1 Physical processing steps : Drying, Delumping 3.5.2 Primary Packaging (enclosing / sealing the active substance within a packaging material which is in direct contact with the substance) 3.5.3 Secondary Packaging (placing the sealed primary package within an outer packaging material or container. This also includes any labelling of the material which could be used for identification or traceability (lot numbering) of the active substance)
3.6	**Quality Control Testing**
	3.6.1 Physical / Chemical testing

Active Substance : BECLABUVIR HYDROCHLORIDE	
3.1	**Manufacture of Active Substance by Chemical Synthesis**
	3.1.1 Manufacture of active substance intermediates 3.1.2 Manufacture of crude active substance 3.1.3 Salt formation / Purification steps : Crystallisation
3.5	**General Finishing Steps**
	3.5.1 Physical processing steps : Drying, Delumping 3.5.2 Primary Packaging (enclosing / sealing the active substance within a packaging material which is in direct contact with the substance) 3.5.3 Secondary Packaging (placing the sealed primary package within an outer packaging material or container. This also includes any labelling of the material which could be used for identification or traceability (lot numbering) of the active substance)
3.6	**Quality Control Testing**
	3.6.1 Physical / Chemical testing

Clarifying remarks (for public users)

This certificate is only applicable to GMP activities performed at the Watery Lane facility from the 1st of January 2018, following the transfer of ownership of the Watery Lane facility from Bristol Meyer Squibb (BMS) to SK Biotek .

2017-12-22

Name and signature of the authorised person of the Competent Authority of Ireland

Health Products Regulatory Authority
Document Reviewed by:
HPRA Reference: C18/0245 Gmp-18-0012
Date: 23rd January 2018

Mr. Paul Sexton
Health Products Regulatory Authority
Tel: *+353 1 676 4971*
Fax: *+353 1 676 4061*

Fingal Dublin Chamber
Advancing business together
Date: 16.03.2018
Accredited Member of Chambers Ireland